ATYR PHARMA INC(ATYR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ATYR ATYR PHARMA INC

Pre-Mkt 08-04 09:03:00 EDT

0.4920

+0.0063

+1.30%

盘前0.5125

+0.0205+4.17%

08:59 EDT

High0.5100	Low0.4801	Vol774.60K
Open0.4928	D1 Closing0.4857	Amplitude6.16%
Mkt Cap48.21M	Tradable Cap47.22M	Total Shares97.99M
T/O382.51K	T/O Rate0.81%	Tradable Shares95.97M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ATYR","market":"US","secType":"STK","nameCN":"ATYR PHARMA INC","latestPrice":0.492,"timestamp":1785787200000,"preClose":0.4857,"halted":0,"volume":774600,"hourTrading":{"tag":"盘前","latestPrice":0.5125,"preClose":0.492,"latestTime":"08:59 EDT","volume":37045,"amount":19038.4071925,"timestamp":1785848396620,"change":0.0205,"changeRate":0.041667,"amplitude":0.111992},"delay":0,"changeRate":0.012970969734403896,"floatShares":95966000,"shares":97986634,"eps":-0.730419,"marketStatus":"Pre-Mkt","change":0.0063,"latestTime":"08-04 09:03:00 EDT","open":0.4928,"high":0.51,"low":0.4801,"amount":382507.301928,"amplitude":0.061561,"askPrice":0.55,"askSize":100,"bidPrice":0.5,"bidSize":1829,"shortable":3,"etf":0,"ttmEps":-0.730419,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1785850200000},"marketStatusCode":1,"adr":0,"listingDate":1430971200000,"exchange":"NASDAQ","adjPreClose":0.492,"preHourTrading":{"tag":"盘前","latestPrice":0.5125,"preClose":0.492,"latestTime":"08:59 EDT","volume":37045,"amount":19038.4071925,"timestamp":1785848396620,"change":0.0205,"changeRate":0.041667,"amplitude":0.111992},"postHourTrading":{"tag":"盘后","latestPrice":0.5,"preClose":0.492,"latestTime":"19:34 EDT","volume":8830,"amount":4402.35318,"timestamp":1785800045649,"change":0.008,"changeRate":0.01626,"amplitude":0.01626},"volumeRatio":1.1957445938092446,"impliedVol":1.3058,"impliedVolPercentile":0.328},"requestUrl":"/m/hq/s/ATYR/tweets","defaultTab":"tweets","newsList":[{"id":"2656304816","title":"Ethos Technologies Q2 Revenue Rises 113% on Policy Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2656304816","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656304816?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:19","pubTimestamp":1785788389,"startTime":"0","endTime":"0","summary":"Ethos Technologies Q2 revenue rises 113% on policy growthOverviewUS life insurance tech firm's Q2 revenue grew 113% yr/yr to $190 mlnNet income for Q2 was $19.5 mln; adjusted EBITDA margin reached 19%","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nL1N440106:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR","BK4173","BK4563","BK4139","LIFE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656820301","title":"aTyr Pharma Q2 Net Income USD 19.531 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2656820301","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656820301?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:05","pubTimestamp":1785787503,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nPLX68GRR2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ATYR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656375707","title":"aTyr Pharma Inc Expected to Post a Loss of 12 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2656375707","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656375707?lang=en_us&edition=fundamental","pubTime":"2026-08-03 19:44","pubTimestamp":1785757459,"startTime":"0","endTime":"0","summary":"aTyr Pharma Inc <ATYR.OQ> expected to post a loss of12cents a share - Earnings PreviewaTyr Pharma IncATYR.OQATYR.Ois expected to  show no change in quarterly revenue when it reports  results on August","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nL8N440124:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATYR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656666391","title":"aTyr Pharma - Co and Kyorin Terminate Collaboration Agreement Effective July 30, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2656666391","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656666391?lang=en_us&edition=fundamental","pubTime":"2026-08-01 04:48","pubTimestamp":1785530883,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nFWN43X2NR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ATYR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656391665","title":"aTyr Pharma - Regains Exclusive Global Rights to Efzofitimod - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2656391665","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656391665?lang=en_us&edition=fundamental","pubTime":"2026-08-01 04:48","pubTimestamp":1785530883,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nFWN43X2NR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATYR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655882330","title":"aTyr Pharma Lawsuit: Company Asks Court to Dismiss Investor Securities Claims","url":"https://stock-news.laohu8.com/highlight/detail?id=2655882330","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655882330?lang=en_us&edition=fundamental","pubTime":"2026-07-29 02:56","pubTimestamp":1785265000,"startTime":"0","endTime":"0","summary":"aTyr Pharma (ATYR) and two executives have asked a federal court to dismiss an amended investor lawsuit over statements tied to the company’s efzof...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/class-action/atyr-pharma-lawsuit-company-asks-court-to-dismiss-investor-securities-claims?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/class-action/atyr-pharma-lawsuit-company-asks-court-to-dismiss-investor-securities-claims?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ATYR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651246836","title":"Atyr Pharma Submits FDA Protocol for Planned Phase 3 Efzofitimod Sarcoidosis Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2651246836","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651246836?lang=en_us&edition=fundamental","pubTime":"2026-07-15 20:02","pubTimestamp":1784116972,"startTime":"0","endTime":"0","summary":"aTyr Pharma submits FDA protocol for planned Phase 3 efzofitimod sarcoidosis studyaTyr Pharma submitted a protocol to the US FDA in June 2026 for a planned Phase 3 study of efzofitimod in chronic, sym","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nNDL1jG7lK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","ATYR","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","BK4585","LU0314104364.USD","LU2095319765.USD","BK4112","IE00BGHQF748.EUR","SG9999014021.USD","SG9999014039.USD","SG9999014005.SGD","SG9999014013.SGD","IE00B3QW5Z07.USD","BCDF","NDAQ","BK4139","LU2210149790.SGD","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","IE00BKPKM429.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651128307","title":"Analysts Conflicted on These Healthcare Names: Tilray (TLRY) and aTyr Pharma (ATYR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2651128307","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651128307?lang=en_us&edition=fundamental","pubTime":"2026-07-14 08:30","pubTimestamp":1783989020,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Tilray (TLRY) and aTyr Pharma (ATYR). Tilray (TLRY...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-tilray-tlry-and-atyr-pharma-atyr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-tilray-tlry-and-atyr-pharma-atyr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","TLRY","XBI","BK4139","LU0029874061.USD","BK4585","HCSG","BK4137","BK4596","XLV","BK4547","LU0128526141.USD","BK4588","BK4557","BK4581","ATYR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650181447","title":"Analysts Offer Insights on Healthcare Companies: aTyr Pharma (ATYR) and CG Oncology, Inc. (CGON)","url":"https://stock-news.laohu8.com/highlight/detail?id=2650181447","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650181447?lang=en_us&edition=fundamental","pubTime":"2026-07-10 18:20","pubTimestamp":1783678834,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on aTyr Pharma (ATYR) and CG Oncology, Inc. (CGON) with...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-atyr-pharma-atyr-and-cg-oncology-inc-cgon-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-atyr-pharma-atyr-and-cg-oncology-inc-cgon-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","XLV","LU0029874061.USD","LABU","CG","XBI","IE00B64PRP62.GBP","HCSG","BK4137","BK4139","ATYR","SBIO","IE00BGHQF748.EUR","BK4135","BK4585","LU0128526141.USD","CGON","BK4588","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642469220","title":"Insider Buyers At aTyr Pharma Likely Disappointed With 19% Slide","url":"https://stock-news.laohu8.com/highlight/detail?id=2642469220","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642469220?lang=en_us&edition=fundamental","pubTime":"2026-06-09 18:02","pubTimestamp":1780999369,"startTime":"0","endTime":"0","summary":"The recent 19% drop in aTyr Pharma, Inc.'s ( NASDAQ:ATYR ) stock could come as a blow to insiders who purchased...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-atyr/atyr-pharma/news/insider-buyers-at-atyr-pharma-likely-disappointed-with-19-sl","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-atyr/atyr-pharma/news/insider-buyers-at-atyr-pharma-likely-disappointed-with-19-sl","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ATYR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642431308","title":"aTyr Pharma wins Nasdaq extension to regain $1 minimum bid price compliance by Nov. 30","url":"https://stock-news.laohu8.com/highlight/detail?id=2642431308","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642431308?lang=en_us&edition=fundamental","pubTime":"2026-06-09 04:05","pubTimestamp":1780949113,"startTime":"0","endTime":"0","summary":"aTyr Pharma received a Nasdaq notice that its shares failed the $1 minimum bid-price rule under Listing Rule 5550.Nasdaq granted a second 180-day compliance period to Nov. 30, 2026; the stock must close at or above $1 for 10 straight sessions.The company flagged a reverse stock split as a potential remedy if it cannot regain compliance through trading performance.Failure to meet the requirement by Nov. 30, 2026 would trigger a delisting notice, with an option to appeal to a Nasdaq hearings panel.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchan","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nNDL9Q3zv1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641016965","title":"Phase 3 Efzofitimod Readout Nears: What ATYR Investors Should Watch in Pulmonary Sarcoidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2641016965","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641016965?lang=en_us&edition=fundamental","pubTime":"2026-06-05 00:31","pubTimestamp":1780590690,"startTime":"0","endTime":"0","summary":"Atyr Pharma Inc. ($ATYR) announced an update on their ongoing clinical study. The Phase 3 study “A Phase 3, Randomized, Double-Blind, Placebo-Contr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/phase-3-efzofitimod-readout-nears-what-atyr-investors-should-watch-in-pulmonary-sarcoidosis?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/phase-3-efzofitimod-readout-nears-what-atyr-investors-should-watch-in-pulmonary-sarcoidosis?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4211","ATYR","ISBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639650616","title":"aTyr Pharma director Paul Schimmel acquires 100,000 common shares valued at $49,630","url":"https://stock-news.laohu8.com/highlight/detail?id=2639650616","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639650616?lang=en_us&edition=fundamental","pubTime":"2026-05-29 04:14","pubTimestamp":1779999255,"startTime":"0","endTime":"0","summary":"aTyr Pharma director Paul Schimmel bought 100,000 common shares at USD 0.5 each.Additional indirect holdings were listed at 1.41 million shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 28, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nNDL1JPMfR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"aTyr Pharma director Paul Schimmel acquires 100,000 common shares valued at $49,630","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637821958","title":"aTyr Pharma Raised to Buy From Hold by Freedom Broker","url":"https://stock-news.laohu8.com/highlight/detail?id=2637821958","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637821958?lang=en_us&edition=fundamental","pubTime":"2026-05-21 00:38","pubTimestamp":1779295080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ATYR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 20, 2026 12:38 ET (16:38 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATYR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636847779","title":"aTyr Pharma upgraded to Buy from Hold at Freedom Broker","url":"https://stock-news.laohu8.com/highlight/detail?id=2636847779","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636847779?lang=en_us&edition=fundamental","pubTime":"2026-05-20 21:00","pubTimestamp":1779282012,"startTime":"0","endTime":"0","summary":"Freedom Broker upgraded aTyr Pharma (ATYR) to Buy from Hold with a price target of $3.50, up from $1. The firm says much of the uncertainty followi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/atyr-pharma-upgraded-to-buy-from-hold-at-freedom-broker-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/atyr-pharma-upgraded-to-buy-from-hold-at-freedom-broker-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ATYR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636885455","title":"RBC Capital Sticks to Its Hold Rating for aTyr Pharma (ATYR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2636885455","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636885455?lang=en_us&edition=fundamental","pubTime":"2026-05-19 09:46","pubTimestamp":1779155209,"startTime":"0","endTime":"0","summary":"In a report released on May 15, Brian Abrahams from RBC Capital maintained a Hold rating on aTyr Pharma, with a price target of $1.00. The company’...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-sticks-to-its-hold-rating-for-atyr-pharma-atyr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-sticks-to-its-hold-rating-for-atyr-pharma-atyr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATYR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636078312","title":"Wells Fargo Sticks to Their Hold Rating for aTyr Pharma (ATYR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2636078312","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636078312?lang=en_us&edition=fundamental","pubTime":"2026-05-18 19:36","pubTimestamp":1779104204,"startTime":"0","endTime":"0","summary":"Wells Fargo analyst Derek Archila maintained a Hold rating on aTyr Pharma today and set a price target of $1.00. Archila covers the Healthcare sect...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wells-fargo-sticks-to-their-hold-rating-for-atyr-pharma-atyr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wells-fargo-sticks-to-their-hold-rating-for-atyr-pharma-atyr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATYR","PGF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635031793","title":"aTyr Pharma Inc options imply 30.5% move in share price post-earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2635031793","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635031793?lang=en_us&edition=fundamental","pubTime":"2026-05-16 01:57","pubTimestamp":1778867822,"startTime":"0","endTime":"0","summary":"Pre-earnings options volume in aTyr Pharma (ATYR) Inc is normal with calls leading puts 142:1. Implied volatility suggests the market is anticipati...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/atyr-pharma-inc-options-imply-30-5-move-in-share-price-post-earnings-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/atyr-pharma-inc-options-imply-30-5-move-in-share-price-post-earnings-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ATYR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635826980","title":"aTyr Pharma Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635826980","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635826980?lang=en_us&edition=fundamental","pubTime":"2026-05-15 20:43","pubTimestamp":1778849000,"startTime":"0","endTime":"0","summary":"aTyr Pharma Inc reports results for the quarter ended March 31 - Earnings SummaryaTyr Pharma Inc ATYR.OQ reported a quarterly adjusted loss of 11 cents per share for the quarter ended March 31, higher","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nL8N41S1BQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATYR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635084659","title":"aTyr Pharma Q1 EPS $(0.11) Beats $(0.14) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635084659","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635084659?lang=en_us&edition=fundamental","pubTime":"2026-05-15 20:17","pubTimestamp":1778847473,"startTime":"0","endTime":"0","summary":"aTyr Pharma (NASDAQ:ATYR) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.14) by 21.43 percent. This is a 35.29 percent increase over losses of $(0.17) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52593660/atyr-pharma-q1-eps-0-11-beats-0-14-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATYR"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.atyrpharma.com","stockEarnings":[{"period":"1week","weight":0.0049},{"period":"1month","weight":-0.1696},{"period":"3month","weight":-0.4158},{"period":"6month","weight":-0.4412},{"period":"1year","weight":-0.8953},{"period":"ytd","weight":-0.3717}],"compareEarnings":[{"period":"1week","weight":0.0251},{"period":"1month","weight":0.0173},{"period":"3month","weight":0.0468},{"period":"6month","weight":0.1042},{"period":"1year","weight":0.2187},{"period":"ytd","weight":0.1111}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.727273,"avgChangeRate":0.035951},{"month":2,"riseRate":0.454545,"avgChangeRate":-0.011862},{"month":3,"riseRate":0.363636,"avgChangeRate":-0.068704},{"month":4,"riseRate":0.363636,"avgChangeRate":-0.026181},{"month":5,"riseRate":0.454545,"avgChangeRate":-0.082646},{"month":6,"riseRate":0.583333,"avgChangeRate":-0.008959},{"month":7,"riseRate":0.416667,"avgChangeRate":-0.016959},{"month":8,"riseRate":0.25,"avgChangeRate":-0.053713},{"month":9,"riseRate":0.454545,"avgChangeRate":0.014241},{"month":10,"riseRate":0.363636,"avgChangeRate":0.029504},{"month":11,"riseRate":0.545455,"avgChangeRate":0.024303},{"month":12,"riseRate":0.454545,"avgChangeRate":-0.061175}],"exchange":"NASDAQ","name":"ATYR PHARMA INC","nameEN":"ATYR PHARMA INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.0","shortVersion":"4.47.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ATYR PHARMA INC(ATYR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ATYR PHARMA INC(ATYR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ATYR PHARMA INC,ATYR,ATYR PHARMA INC股票,ATYR PHARMA INC股票老虎,ATYR PHARMA INC股票老虎国际,ATYR PHARMA INC行情,ATYR PHARMA INC股票行情,ATYR PHARMA INC股价,ATYR PHARMA INC股市,ATYR PHARMA INC股票价格,ATYR PHARMA INC股票交易,ATYR PHARMA INC股票购买,ATYR PHARMA INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ATYR PHARMA INC(ATYR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ATYR PHARMA INC(ATYR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}